Table 1 Frequencies of CYP2D6 alleles in the Arab countries
From: Frequencies of CYP2D6 genetic polymorphisms in Arab populations
Country/References | No. of individuals | Subject type | Genotyping method | Alleles’ activity | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Normal | Reduced | Non-functional | |||||||||
*2 | *10 | *17 | *41 | *3 | *4 | *5 | *6 | ||||
Algeria (Mozabite) [20] | 30 | – | Long PCR | 28.3 | 0 | 8.3 | 8.3 | 0 | 11.7 | 3.3 | 0 |
Egypt [12] | 308 | Healthy fertile + infertile men | RFLP analysis | – | – | – | – | – | 25.6 | – | – |
Egypt [13] | 29 | Healthy subjects | RFLP analysis | – | – | – | – | – | 18.1 | – | – |
40 | Acute OPa intoxicated patients | ||||||||||
Egypt [14] | 29 | Healthy subjects | RFLP analysis | – | – | – | – | – | 22.0 | – | – |
30 | Chronic OPa exposed patients | ||||||||||
Egypt [21] | 145 | Healthy subjects | TaqMan | 31.3 | 3.4 | – | 15.1 | – | 9.6 | 2.0 | – |
Iraq [15] | 250 | ACSb patients | RFLP analysis | 7.6 | 13.4 | 9.2 | – | – | 6.8 | – | – |
Jordan [16] | 192 | Healthy subjects | RFLP analysis | – | 14.8 | 8.3 | – | – | 12.8 | – | – |
Lebanon [22] | 111 | Breast cancer patients | Real-time PCR | – | – | – | 12.1 | 0.9 | 15.9 | – | – |
Morocco [17] | 200 | Healthy subjects | RFLP analysis | – | 8.5 | – | – | 11.13 | 10.1 | – | – |
200 | Breast cancer patients | ||||||||||
Palestine [20] | 51 | – | Long PCR | 27.5 | 2.0 | 2.0 | 12.7 | 0 | 7.8 | 1.0 | 2.0 |
Saudi Arabia [23] | 192 | Healthy subjects | Sequencing | – | – | – | 18.4 | 0 | – | – | 0 |
Saudi Arabia [18] | 101 | Healthy subjects | RFLP analysis | – | 3.0 | 3.0 | – | – | 3.5 | 1.0 | – |
Syria [24] | 51 | Healthy subjects | Long PCR | 30.39 | 2.94 | 0 | – | 0 | 9.8 | 0.98 | 0.98 |
Syria unpublished data | 97 | Breast cancer patients | Sequencing | – | 7.2 | – | 9.28 | – | 7.2 | – | – |
Tunisia [19] | 300 | Breast cancer patients | RFLP analysis | – | – | – | – | – | 13.39 | – | – |
230 | Healthy subjects | ||||||||||
UAE [25] | 101 | Psychiatric patients | Sequencing | 12.2 | 3.3 | 2.5 | 15.2 | 0 | 9.0 | – | 0 |
50 | Healthy subjects | ||||||||||